Secular Trends in the Utilization of Systemic Lysis and Catheter Directed Thrombectomy in the Treatment of Intermediate and High-Risk PE

ADVOCATE HEALTH

Authors: Kristina Strupp, MSN, RN, APNP, AGCNS-BC, M. Fuad, Jan, MD, FACC, FSCAI, Niloufar Javadi, MD, Louie Kostopoulos, MD, FACC

Author Email: Kristina.Strupp@aah.org Aurora St. Luke's Medical Center, Milwaukee, WI

Background

- The Pulmonary Embolism Response Team (PERT) program at our 938-bed quaternary medical center was founded in March 2017
- A collaborative effort between Critical Care and Interventional Cardiology, as one of the founding members of the National PERT Consortium™.
- The program is a protocol, data-driven model, reflecting best evidence by:
 - Continuously refining the treatment protocol
 - Activation algorithm
 - Care recommendations
- Key program growth and refinement initiatives include:




Figure 1. Key program milestones

Purpose

This analysis aimed to examine the trends in treatment decisions for intermediate and high-risk pulmonary embolism (PE) within a single site's PERT program

Methods

A retrospective analysis of the treatment provided to all intermediate and high-risk patients admitted to the site between 2021-2024 was conducted

Methods Cont.

- De-identified patient information was compared with Chi-square test between those that received anticoagulation alone vs systemic lysis or catheter directed thrombectomy (CDT)
- Of note, during this timeframe in late 2022, the site began enrolling in two different PE trials

Results

The analysis included treatment of (n=683) patients hospitalized with acute intermediate and high-risk PE over four years (Figure 2 & Table 1)




Figure 2. Secular treatment trends 2021-2024

| | 2021 | 2024 | |
|--------------------------------|-----------|----------|---------|
| Treatment Modality | n (%) | n (%) | p-value |
| Anticoagulation Alone | 132 (71%) | 87 (57%) | 0.005 |
| Systemic Lysis | 41 (22%) | 25 (16%) | 0.188 |
| Catheter Directed Thrombectomy | 12 (6%) | 41 (27%) | < 0.001 |

Table 1:. Summary of treatment trends

Conclusions

- This analysis reveals a significant shift in the therapeutic approach to intermediate and high-risk PE within a singlesite PERT program
- Over the four-year study period, there was a marked increase in the use of CDT, rising from 6% in 2021 to 27% in 2024
- This trend reflects growing confidence in catheter-based interventions, likely influenced by evolving clinical experience, protocol refinement, and participation in ongoing PE trials
- This may influence future guidelines in management strategies for PE as trial data and real-world experience coalesce

Implications for Practice

- Continued participation in national registries and structured case reviews supports benchmarking and quality assurance
- These efforts can help identify best practices, track outcomes, and guide future research priorities
- Future work to include evaluation of clinical outcomes of selected treatment
- The single-center design limits generalizability. Future multicenter studies are needed to validate these trends and assess long-term outcomes, cost-effectiveness, and patientcentered metrics

Acknowledgements

Aurora St. Luke's Medical Center PERT Program Leadership in addition to authors: Dr. Eric Siegal, Dr. Jason Tomasello, Dr. Afzal Ammar & Dr. Hesham Elghannam

Jeannie Hlebichuk, PhD, Nurse Scientist & Nursing Research Manager

Dr. Tanvir Bajwa, Head of Aurora Cardiovascular Service Line Interventional Program

Dr. Suhail Allaqaband, Senior Medical Director, Aurora Cardiovascular Service line





